What is Breyna’s market share (and which market)?
“Breyna” is the brand name for a budesonide/formoterol inhaler (used for asthma control). Market share figures depend heavily on what you mean by “market,” such as:
- the total inhaled corticosteroid/long-acting bronchodilator (ICS/LABA) class,
- the U.S. asthma inhaler market,
- a specific payer channel (e.g., Medicaid vs. commercial),
- or a specific geography and time period.
With the information provided here, I can’t give a specific Breyna market share percentage without knowing the country, year, and market definition you’re looking for.
Where to find the market-share data people usually use
Drug market share is typically reported by:
- IQVIA and other payer/pharmacy analytics firms,
- company investor materials (often for specific products/segments),
- and industry trade reporting that cites those data.
If you tell me your target (for example, “U.S., 2023, asthma ICS/LABA”), I can point you to the most relevant published market-share source.
Patent/competition context that can affect Breyna’s share
Breyna’s share is influenced by competitive dynamics in ICS/LABA inhalers (including branded competitors and any available generics/biosimilars in adjacent segments). Patent status and exclusivity can also drive entry timing for competitors. For patent-linked tracking, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/.
Quick questions so I can give the exact number you want
1) What geography: U.S., EU, or another country?
2) What year/quarter?
3) What market definition: total asthma inhalers, ICS/LABA class, or a payer channel?
Share those details and I’ll respond with the specific market share figure(s) that match your definition and time frame.